Document Detail

A comparative study of recombinant human basic fibroblast growth factor (bFGF) and erythropoietin (EPO) in prevention of skin flap ischemic necrosis in rats.
MedLine Citation:
PMID:  22924373     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Impaired wound healing in ischemic tissues such as skin flaps resulting from inefficient perfusion is one major cause of complications in plastic surgery. In present experimental study, we investigated the effects of fibroblast growth factor-2 (FGF-2 or bFGF) and erythropoietin (EPO) in prevention of skin flap necrosis in rats.
METHODS: 30 adult albino rats were randomized into 3 groups: in control group, normal saline solution; in EPO group, erythropoietin (100U/kg/day); and in FGF-2 group, fibroblast growth factor-2 (2.5µg/day) were injected subcutaneously in 3 daily consecutive doses in the designated flap areas before creating 4:1 random pattern skin flaps on the dorsum of animals. Areas of ischemic (SI) and necrotic (SN) zones were measured and compared in all groups one week after the flap creations.
RESULTS: The necrotic zone (SN), as well as the ratio of the necrotic zone to the total discolored zone (SN/[SI+SN]) were substantially larger in the control group (41%±7%, 90%±6%) compared to the EPO (20%±2%, 42%±4%)  and the FGF-2 (8%±2%, 19%±3%) groups (p<0.001). The differences in these values were also meaningful between the EPO and FGF-2 groups (p<0.001).Vascular density in ischemic area of the control group was less than those in the EPO and the FGF-2 groups; however, the differences were not statistically significant between any of the groups (p>0.05).
CONCLUSIONS: Local administration of erythropoietin or fibroblast growth factor-2 in skin flaps could remarkably increase tissue viability and accelerate the wound healing process. However, the therapeutic effect of fibroblast growth factor-2 in preventing the necrotic event in ischemic zones of skin flaps is much more considerable than that of erythropoietin.
Ehsan Fayazzadeh; Seyed Hossein Ahmadi; Shahram Rabbani; Mohammad Ali Boroumand; Ali Salavati; Maryam Sotoudeh Anvari
Related Documents :
23799893 - Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitar...
1200283 - Repair of peristomal colostomy hernias.
9107393 - Botulinum toxin in fourth nerve palsies.
Publication Detail:
Type:  Comparative Study; Evaluation Studies; Journal Article    
Journal Detail:
Title:  Archives of Iranian medicine     Volume:  15     ISSN:  1735-3947     ISO Abbreviation:  Arch Iran Med     Publication Date:  2012 Sep 
Date Detail:
Created Date:  2012-08-28     Completed Date:  2013-01-11     Revised Date:  2013-05-15    
Medline Journal Info:
Nlm Unique ID:  100889644     Medline TA:  Arch Iran Med     Country:  Iran    
Other Details:
Languages:  eng     Pagination:  553-6     Citation Subset:  IM    
Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiogenesis Inducing Agents / therapeutic use*
Drug Administration Schedule
Erythropoietin / therapeutic use*
Fibroblast Growth Factor 2 / therapeutic use*
Graft Survival
Injections, Subcutaneous
Ischemia / complications*
Necrosis / etiology,  prevention & control*
Random Allocation
Rats, Sprague-Dawley
Recombinant Proteins / therapeutic use*
Surgical Flaps / blood supply,  pathology*
Wound Healing
Reg. No./Substance:
0/Angiogenesis Inducing Agents; 0/KCB-1 protein, recombinant; 0/Recombinant Proteins; 103107-01-3/Fibroblast Growth Factor 2; 11096-26-7/Erythropoietin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effect of fish oil supplements on serum paraoxonase activity in female patients with rheumatoid arth...
Next Document:  Effect of intra-amygdala injection of lipopolysaccharide on kindling epileptogenesis in adult rats.